Movement Alert｜Sino Biopharmaceutical Rises 3.13% in Regular Trading, Pharma Sector Rebounds as Multiple Recent Catalysts Continue to Ferment

Market Focus

Jul 22

On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.

The pharmaceutical sector broadly recovered, with CSPC Pharma up 0.36%, Hansoh Pharma up 1.84%, and Hengrui Pharma up 1.59%. The company has accumulated multiple positive catalysts in recent weeks: on July 14, its subsidiary's TRD205 (AT2R antagonist) received Breakthrough Therapy Designation from China's CDE for chronic painful peripheral neuropathy; on July 10, the NDA for IDH1 inhibitor TQB3454 targeting advanced biliary tract cancer was accepted by regulators and entered priority review; on July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration of up to $1.9 billion including a $200 million upfront payment, while simultaneously deepening its strategic partnership with GSK in respiratory therapeutics. Multiple brokerages maintain Buy ratings, with target prices of 8.70 HKD and 7.70 HKD respectively.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1118649221"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118649221\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118649221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118649221","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Rises 3.13% in Regular Trading, Pharma Sector Rebounds as Multiple Recent Catalysts Continue to Ferment","media":"Market Focus","content":"<p><p>On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.</p><p>The pharmaceutical sector broadly recovered, with CSPC Pharma up 0.36%, Hansoh Pharma up 1.84%, and Hengrui Pharma up 1.59%. The company has accumulated multiple positive catalysts in recent weeks: on July 14, its subsidiary's TRD205 (AT2R antagonist) received Breakthrough Therapy Designation from China's CDE for chronic painful peripheral neuropathy; on July 10, the NDA for IDH1 inhibitor TQB3454 targeting advanced biliary tract cancer was accepted by regulators and entered priority review; on July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration of up to $1.9 billion including a $200 million upfront payment, while simultaneously deepening its strategic partnership with GSK in respiratory therapeutics. Multiple brokerages maintain Buy ratings, with target prices of 8.70 HKD and 7.70 HKD respectively.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Rises 3.13% in Regular Trading, Pharma Sector Rebounds as Multiple Recent Catalysts Continue to Ferment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Rises 3.13% in Regular Trading, Pharma Sector Rebounds as Multiple Recent Catalysts Continue to Ferment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.</p><p>The pharmaceutical sector broadly recovered, with CSPC Pharma up 0.36%, Hansoh Pharma up 1.84%, and Hengrui Pharma up 1.59%. The company has accumulated multiple positive catalysts in recent weeks: on July 14, its subsidiary's TRD205 (AT2R antagonist) received Breakthrough Therapy Designation from China's CDE for chronic painful peripheral neuropathy; on July 10, the NDA for IDH1 inhibitor TQB3454 targeting advanced biliary tract cancer was accepted by regulators and entered priority review; on July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration of up to $1.9 billion including a $200 million upfront payment, while simultaneously deepening its strategic partnership with GSK in respiratory therapeutics. Multiple brokerages maintain Buy ratings, with target prices of 8.70 HKD and 7.70 HKD respectively.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1118649221","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118649221","pubTimestamp":1784685097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"走势提醒|中国生物制药常规交易上涨3.13%，医药板块反弹，近期多重催化剂持续发酵","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.The pharmaceutical sector broadly recovered, with CSPC Pharma up 0.36%, Hansoh Pharma up 1.84%, and Hengrui Pharma up 1.59%. The company has accumulated multiple positive catalysts in recent weeks: on July 14, its subsidiary's TRD205 (AT2R antagonist) received Breakthrough Therapy Designation from China's CDE for chronic painful peripheral neuropathy; on July 10, the NDA for IDH1 inhibitor TQB3454 targeting advanced biliary tract cancer was accepted by regulators and entered priority review; on July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration of up to $1.9 billion including a $200 million upfront payment, while simultaneously deepening its strategic partnership with GSK in respiratory therapeutics. Multiple brokerages maintain Buy ratings, with target prices of 8.70 HKD and 7.70 HKD respectively.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}